A detailed case report shows that neoadjuvant combination immunotherapy can activate antitumor immunity and drive clinical benefit in newly diagnosed glioblastoma, revealing avenues for further research that could shift the treatment landscape to improve survival.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lim, M. et al. Neuro. Oncol. 24, 1935–1949 (2022).
Long, G. V., Shklovskaya, E. & Rizos, H. Nat. Med. https://doi.org/10.1038/s41591-025-03512-1 (2025).
Cloughesy, T. F. et al. Nat. Med. 25, 477–486 (2019).
Schalper, K. A. et al. Nat. Med. 25, 470–476 (2019).
Roth, P., Valavanis, A. & Weller, M. Neuro. Oncol. 19, 454–456 (2017).
Miller, T. E. et al. Nature https://doi.org/10.1038/s41586-025-08633-8 (2025).
Nassiri, F. et al. Nat. Med. 26, 1044–1047 (2020).
Fathi Kazerooni, A. et al. Nat. Commun. 16, 340 (2025).
Galanis, E. et al. Nat. Commun. 15, 493 (2024).
Nassiri, F. et al. Nat. Med. 29, 1370–1378 (2023).
Ling, A. L. et al. Nature 623, 157–166 (2023).
Choi, B. D. et al. N. Engl. J. Med. 390, 1290–1298 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ellenbogen, Y., Zadeh, G. A new paradigm for immunotherapy in glioblastoma. Nat Med 31, 1404–1405 (2025). https://doi.org/10.1038/s41591-025-03607-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03607-9
